Evaluation of Heliconia for growth, flowering and flower yield

Heliconia is utilized as ornamental plants, usually being grown both as landscaping plants and as cut flowers, owing to colour and the longer durability of its floral bracts. Forty-one genotypes of Heliconia were evaluated for growth, flowering and flower yield. Significant variation was observed among genotypes for vegetative and floral characteristics. The results revealed that the maximum number of leaves per sucker was recorded in H. hirsuta followed by H. ‘Golden Torch Adrian’ and H. ‘GT Sunshine’, while, maximum plant height was recorded in varieties viz., H. caribea (459.33 cm) followed by H. ‘She’ (337.67 cm) and H. rauliniana upright (305.00 cm). However, maximum leaf length was observed in H. caribea (314.33 cm) followed by H. ‘She’ (203.67 cm) and Heliconia metallica (175.00 cm). Maximum sucker production was recorded in H. ‘Tropics’ followed by H. psittacorum ‘Petra’ and H. ‘Guyana’. Among the flowering traits, early flower initiation was recorded in Golden Torch (136.00 days) followed by Lady Di (152.00 days). The rachis length ranged from 72.67 cm (H. ‘Golden Torch’) to 10.00 cm (H. ‘Hirsuta’), however, longest spike was recorded in H. ‘rauliniana upright’ (131.33 cm) followed by H. rostrata ‘Parrots Beak’ (115.67 cm) and H. rostrata Ten Days (97.00 cm), whereas, shortest spike was recorded in H. bihai (9.33 cm)

Evaluation of Heliconia for growth, flowering and flower yield

Heliconia is utilized as ornamental plants, usually being grown both as landscaping plants and as cut flowers, owing to colour and the longer durability of its floral bracts. Forty-one genotypes of Heliconia were evaluated for growth, flowering and flower yield. Significant variation was observed among genotypes for vegetative and floral characteristics. The results revealed that the maximum number of leaves per sucker was recorded in H. hirsuta followed by H. ‘Golden Torch Adrian’ and H. ‘GT Sunshine’, while, maximum plant height was recorded in varieties viz., H. caribea (459.33 cm) followed by H. ‘She’ (337.67 cm) and H. rauliniana upright (305.00 cm). However, maximum leaf length was observed in H. caribea (314.33 cm) followed by H. ‘She’ (203.67 cm) and Heliconia metallica (175.00 cm). Maximum sucker production was recorded in H. ‘Tropics’ followed by H. psittacorum ‘Petra’ and H. ‘Guyana’. Among the flowering traits, early flower initiation was recorded in Golden Torch (136.00 days) followed by Lady Di (152.00 days). The rachis length ranged from 72.67 cm (H. ‘Golden Torch’) to 10.00 cm (H. ‘Hirsuta’), however, longest spike was recorded in H. ‘rauliniana upright’ (131.33 cm) followed by H. rostrata ‘Parrots Beak’ (115.67 cm) and H. rostrata Ten Days (97.00 cm), whereas, shortest spike was recorded in H. bihai (9.33 cm)

Use of multidimensional item response theory methods for dementia prevalence prediction : an example using the Health and Retirement Survey and the Aging, Demographics, and Memory Study

Background Data sparsity is a major limitation to estimating national and global dementia burden. Surveys with full diagnostic evaluations of dementia prevalence are prohibitively resource-intensive in many settings. However, validation samples from nationally representative surveys allow for the development of algorithms for the prediction of dementia prevalence nationally. Methods Using cognitive testing data and data on functional limitations from Wave A (2001-2003) of the ADAMS study (n = 744) and the 2000 wave of the HRS study (n = 6358) we estimated a two-dimensional item response theory model to calculate cognition and function scores for all individuals over 70. Based on diagnostic information from the formal clinical adjudication in ADAMS, we fit a logistic regression model for the classification of dementia status using cognition and function scores and applied this algorithm to the full HRS sample to calculate dementia prevalence by age and sex. Results Our algorithm had a cross-validated predictive accuracy of 88% (86-90), and an area under the curve of 0.97 (0.97-0.98) in ADAMS. Prevalence was higher in females than males and increased over age, with a prevalence of 4% (3-4) in individuals 70-79, 11% (9-12) in individuals 80-89 years old, and 28% (22-35) in those 90 and older. Conclusions Our model had similar or better accuracy as compared to previously reviewed algorithms for the prediction of dementia prevalence in HRS, while utilizing more flexible methods. These methods could be more easily generalized and utilized to estimate dementia prevalence in other national surveys

Spatial, temporal, and demographic patterns in prevalence of chewing tobacco use in 204 countries and territories, 1990-2019 : a systematic analysis from the Global Burden of Disease Study 2019

Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and policies that specifically target use of chewing tobacco, especially in countries with high prevalence. Findings In 2019, 273 center dot 9 million (95% uncertainty interval 258 center dot 5 to 290 center dot 9) people aged 15 years and older used chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4 center dot 72% (4 center dot 46 to 5 center dot 01). 228 center dot 2 million (213 center dot 6 to 244 center dot 7; 83 center dot 29% [82 center dot 15 to 84 center dot 42]) chewing tobacco users lived in the south Asia region. Prevalence among young people aged 15-19 years was over 10% in seven locations in 2019. Although global agestandardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: -1 center dot 21% [-1 center dot 26 to -1 center dot 16]), similar progress was not observed for chewing tobacco (0 center dot 46% [0 center dot 13 to 0 center dot 79]). Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of chewing tobacco use, which was among males between 1990 and 2019 (-0 center dot 94% [-1 center dot 72 to -0 center dot 14]), compared with nine of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a significant decrease in the prevalence of tobacco smoking use for the period. Summary Background Chewing tobacco and other types of smokeless tobacco use have had less attention from the global health community than smoked tobacco use. However, the practice is popular in many parts of the world and has been linked to several adverse health outcomes. Understanding trends in prevalence with age, over time, and by location and sex is important for policy setting and in relation to monitoring and assessing commitment to the WHO Framework Convention on Tobacco Control. Methods We estimated prevalence of chewing tobacco use as part of the Global Burden of Diseases, Injuries, and Risk Factors Study 2019 using a modelling strategy that used information on multiple types of smokeless tobacco products. We generated a time series of prevalence of chewing tobacco use among individuals aged 15 years and older from 1990 to 2019 in 204 countries and territories, including age-sex specific estimates. We also compared these trends to those of smoked tobacco over the same time period. Findings In 2019, 273 & middot;9 million (95% uncertainty interval 258 & middot;5 to 290 & middot;9) people aged 15 years and older used chewing tobacco, and the global age-standardised prevalence of chewing tobacco use was 4 & middot;72% (4 & middot;46 to 5 & middot;01). 228 & middot;2 million (213 & middot;6 to 244 & middot;7; 83 & middot;29% [82 & middot;15 to 84 & middot;42]) chewing tobacco users lived in the south Asia region. Prevalence among young people aged 15-19 years was over 10% in seven locations in 2019. Although global age standardised prevalence of smoking tobacco use decreased significantly between 1990 and 2019 (annualised rate of change: -1 & middot;21% [-1 & middot;26 to -1 & middot;16]), similar progress was not observed for chewing tobacco (0 & middot;46% [0 & middot;13 to 0 & middot;79]). Among the 12 highest prevalence countries (Bangladesh, Bhutan, Cambodia, India, Madagascar, Marshall Islands, Myanmar, Nepal, Pakistan, Palau, Sri Lanka, and Yemen), only Yemen had a significant decrease in the prevalence of chewing tobacco use, which was among males between 1990 and 2019 (-0 & middot;94% [-1 & middot;72 to -0 & middot;14]), compared with nine of 12 countries that had significant decreases in the prevalence of smoking tobacco. Among females, none of these 12 countries had significant decreases in prevalence of chewing tobacco use, whereas seven of 12 countries had a significant decrease in the prevalence of tobacco smoking use for the period. Interpretation Chewing tobacco remains a substantial public health problem in several regions of the world, and predominantly in south Asia. We found little change in the prevalence of chewing tobacco use between 1990 and 2019, and that control efforts have had much larger effects on the prevalence of smoking tobacco use than on chewing tobacco use in some countries. Mitigating the health effects of chewing tobacco requires stronger regulations and policies that specifically target use of chewing tobacco, especially in countries with high prevalence. Copyright (c) 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.Peer reviewe

Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019

Background Sustainable Development Goal 3.2 has targeted elimination of preventable child mortality, reduction of neonatal death to less than 12 per 1000 livebirths, and reduction of death of children younger than 5 years to less than 25 per 1000 livebirths, for each country by 2030. To understand current rates, recent trends, and potential trajectories of child mortality for the next decade, we present the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 findings for all-cause mortality and cause-specific mortality in children younger than 5 years of age, with multiple scenarios for child mortality in 2030 that include the consideration of potential effects of COVID-19, and a novel framework for quantifying optimal child survival. Methods We completed all-cause mortality and cause-specific mortality analyses from 204 countries and territories for detailed age groups separately, with aggregated mortality probabilities per 1000 livebirths computed for neonatal mortality rate (NMR) and under-5 mortality rate (USMR). Scenarios for 2030 represent different potential trajectories, notably including potential effects of the COVID-19 pandemic and the potential impact of improvements preferentially targeting neonatal survival. Optimal child survival metrics were developed by age, sex, and cause of death across all GBD location-years. The first metric is a global optimum and is based on the lowest observed mortality, and the second is a survival potential frontier that is based on stochastic frontier analysis of observed mortality and Healthcare Access and Quality Index. Findings Global U5MR decreased from 71.2 deaths per 1000 livebirths (95% uncertainty interval WI] 68.3-74-0) in 2000 to 37.1 (33.2-41.7) in 2019 while global NMR correspondingly declined more slowly from 28.0 deaths per 1000 live births (26.8-29-5) in 2000 to 17.9 (16.3-19-8) in 2019. In 2019,136 (67%) of 204 countries had a USMR at or below the SDG 3.2 threshold and 133 (65%) had an NMR at or below the SDG 3.2 threshold, and the reference scenario suggests that by 2030,154 (75%) of all countries could meet the U5MR targets, and 139 (68%) could meet the NMR targets. Deaths of children younger than 5 years totalled 9.65 million (95% UI 9.05-10.30) in 2000 and 5.05 million (4.27-6.02) in 2019, with the neonatal fraction of these deaths increasing from 39% (3.76 million 95% UI 3.53-4.021) in 2000 to 48% (2.42 million; 2.06-2.86) in 2019. NMR and U5MR were generally higher in males than in females, although there was no statistically significant difference at the global level. Neonatal disorders remained the leading cause of death in children younger than 5 years in 2019, followed by lower respiratory infections, diarrhoeal diseases, congenital birth defects, and malaria. The global optimum analysis suggests NMR could be reduced to as low as 0.80 (95% UI 0.71-0.86) deaths per 1000 livebirths and U5MR to 1.44 (95% UI 1-27-1.58) deaths per 1000 livebirths, and in 2019, there were as many as 1.87 million (95% UI 1-35-2.58; 37% 95% UI 32-43]) of 5.05 million more deaths of children younger than 5 years than the survival potential frontier. Interpretation Global child mortality declined by almost half between 2000 and 2019, but progress remains slower in neonates and 65 (32%) of 204 countries, mostly in sub-Saharan Africa and south Asia, are not on track to meet either SDG 3.2 target by 2030. Focused improvements in perinatal and newborn care, continued and expanded delivery of essential interventions such as vaccination and infection prevention, an enhanced focus on equity, continued focus on poverty reduction and education, and investment in strengthening health systems across the development spectrum have the potential to substantially improve USMR. Given the widespread effects of COVID-19, considerable effort will be required to maintain and accelerate progress. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd

Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990–2019: results from the Global Burden of Disease Study 2019

Background Tuberculosis is a major contributor to the global burden of disease, causing more than a million deaths annually. Given an emphasis on equity in access to diagnosis and treatment of tuberculosis in global health targets, evaluations of differences in tuberculosis burden by sex are crucial. We aimed to assess the levels and trends of the global burden of tuberculosis, with an emphasis on investigating differences in sex by HIV status for 204 countries and territories from 1990 to 2019. Methods We used a Bayesian hierarchical Cause of Death Ensemble model (CODEm) platform to analyse 21 505 site-years of vital registration data, 705 site-years of verbal autopsy data, 825 site-years of sample-based vital registration data, and 680 site-years of mortality surveillance data to estimate mortality due to tuberculosis among HIV-negative individuals. We used a population attributable fraction approach to estimate mortality related to HIV and tuberculosis coinfection. A compartmental meta-regression tool (DisMod-MR 2.1) was then used to synthesise all available data sources, including prevalence surveys, annual case notifications, population-based tuberculin surveys, and tuberculosis cause-specific mortality, to produce estimates of incidence, prevalence, and mortality that were internally consistent. We further estimated the fraction of tuberculosis mortality that is attributable to independent effects of risk factors, including smoking, alcohol use, and diabetes, for HIV-negative individuals. For individuals with HIV and tuberculosis coinfection, we assessed mortality attributable to HIV risk factors including unsafe sex, intimate partner violence (only estimated among females), and injection drug use. We present 95% uncertainty intervals for all estimates. Findings Globally, in 2019, among HIV-negative individuals, there were 1.18 million (95% uncertainty interval 1.08-1.29) deaths due to tuberculosis and 8.50 million (7.45-9.73) incident cases of tuberculosis. Among HIV-positive individuals, there were 217 000 (153 000-279 000) deaths due to tuberculosis and 1.15 million (1.01-1.32) incident cases in 2019. More deaths and incident cases occurred in males than in females among HIV-negative individuals globally in 2019, with 342 000 (234 000-425 000) more deaths and 1.01 million (0.82-1.23) more incident cases in males than in females. Among HIV-positive individuals, 6250 (1820-11 400) more deaths and 81 100 (63 300-100 000) more incident cases occurred among females than among males in 2019. Age-standardised mortality rates among HIV-negative males were more than two times greater in 105 countries and age-standardised incidence rates were more than 1.5 times greater in 74 countries than among HIV-negative females in 2019. The fraction of global tuberculosis deaths among HIV-negative individuals attributable to alcohol use, smoking, and diabetes was 4.27 (3.69-5.02), 6.17 (5.48-7.02), and 1.17 (1.07-1.28) times higher, respectively, among males than among females in 2019. Among individuals with HIV and tuberculosis coinfection, the fraction of mortality attributable to injection drug use was 2.23 (2.03-2.44) times greater among males than females, whereas the fraction due to unsafe sex was 1.06 (1.05-1.08) times greater among females than males. Interpretation As countries refine national tuberculosis programmes and strategies to end the tuberculosis epidemic, the excess burden experienced by males is important. Interventions are needed to actively communicate, especially to men, the importance of early diagnosis and treatment. These interventions should occur in parallel with efforts to minimise excess HIV burden among women in the highest HIV burden countries that are contributing to excess HIV and tuberculosis coinfection burden for females. Placing a focus on tuberculosis burden among HIV-negative males and HIV and tuberculosis coinfection among females might help to diminish the overall burden of tuberculosis. This strategy will be crucial in reaching both equity and burden targets outlined by global health milestone

Not Available

Not Available1. Introduction 1 2. Major Highlights 4 3. Salient Research Achievements 7 4. Progress Report Discipline wise I. Germplasm Conservation and Evaluation 18 II. Crop Improvement 191 III. Crop Management 295 IV. Crop Protection 462 V. Postharvest Technology and Value Addition 488 5. Publications 592 6. Success Stories 604 7. New Initiatives 606 8. Production & Distribution of Planting Materials 610 9. Training Organized 613 10. Training/ Seminar/ Symposium Attended 615 11. Staff Position 618 12. Name and Addresses of Officers-in-Charge 624 of AICRP Centres 13. Budget (2017-18) 628Not Availabl

Not Available

Not AvailableNot AvailableNot Availabl

Not Available

Not AvailableFloriculture is becoming important for domestic and export markets and the demand is ever increasing. Opportunities for floriculture and landscape gardening are increasing due to urbanization and enhanced expendable income. In the fast changing global context, managing the change on a time scale, by converting weakness into opportunities to become internationally competitive is considered important. The increasing demand for both cut flowers and potted plants in Western countries will result in the production gain from our country. The scope expands further by increasing the production of exiting product as well as expanding the product range. There has been an appreciable increase in floriculture, but potentialities, which exit in the sector, have not been harnessed. The sector has lot of potential to address social and economic issues including employment generation, private sector investment, entrepreneurship, job for unemployed educated youths and women empowerment. The All India Coordinated Research Project on Floriculture was started during IV-Five Year Plan (in the year 1970-71) to initiate scientific research on floriculture. Initially there were 5 centres which were reorganized from time to time and at present the coordinated project has 21 Centres which includes 15 budgetary, 4 Institutional and 2 Voluntary, covering 17 states of India. Since its inception, the AICRP has made substantial progress in development of new and improved varieties of flower crops, standardization of production technology including improved plant protection measures and post harvest management. The mandate of AICRPs is not only the testing of verities and agrotechniques but also identification of location specific problems and their solutions. When experiments are conducted at many locations and many personnel are involved, it is necessary that common methodology is followed so that the results can be compared across locations. Proper care has also to be taken in recording observations so that we can understand the crop phenology vis a vis the environment. There, is a need to delineate a uniform set of essential observations that have to be recorded in all the experiments which would help express the phenology of the crop affected by the environment or treatments. Moreover, such a systematic list of observations would help to adopt a systematic analysis protocol. Further, the personnel conducting the trials at different centers are of widely different background, hence, well described protocols for conduct of the trials as well as recording observations would reduce the human errors in recording of observations. Hence, a need was often felt to develop a technical manual on standard operating procedures that will give clear cut guidelines for the personnel involved in conduct of field experiments and recording the observations. An effort is therefore made to bring about this publication entitled Standard Operational Procedures for Conducting Field Experiments under AICRP on Floriculture.Not Availabl

Not Available

Not AvailableReleased during the Foundation Stone Laying Ceremony of Farm Office cum Field Laboratory on August 3, 2019Not Availabl